Drug Profile
Filgrastim biosimilar - USV
Alternative Names: Granulocyte colony stimulating factors biosmilar - USVLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator USV
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Neutropenia in India (SC, Injection)
- 11 May 2015 Preclinical trials in Neutropenia in India (SC) (USV product pipeline, May 2015)